MRK250502P85000
- 1.14
- +0.17+17.53%
Merck & Co Newsroom
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $108
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness' Stock Picks With Huge Upside Potential
Express News | Merck & Co Inc : Guggenheim Cuts Target Price to $108 From $115
Honeywell, Sherwin-Williams Co. Share Gains Lead Dow's 232-Point Jump
Express News | Merck & Co: Laboratory Component Is Expected to Be Fully Operational by 2028, With Production of Investigational Compounds to Start by 2030
Express News | Merck & Co Inc: Merck Wilmington Biotech Will Serve as a Launch and Commercial Production Facility and Future U.S. Home for Keytruda
Express News | Merck & Co Inc - New Facility to Create 500 Full-Time Roles and 4,000 Jobs
Express News | Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
Merck (MRK.US) plans to invest 1 billion USD to build a factory in the USA to ensure the supply of Keytruda is protected from tariff impacts.
Merck will invest 1 billion dollars to build a factory in Delaware to ensure the domestic supply of Keytruda.
Merck to Build $1B Delaware Plant to Ensure Domestic Supply of Keytruda - Report
Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug -- WSJ
New Analyst Forecast: $MRK Given $82.0 Price Target
9 Health Care Stocks Whale Activity In Today's Session
Unusual Options Activity: CRM, MRK and Others Attract Market Bets, CRM V/OI Ratio Reaches 231.7
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Today's Analyst Rating | Apple Price Target Raised to $235 by Morgan Stanley, HSBC Cuts Its Price Target Cut on Merck & Co to $100
HSBC Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $100
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Merck's Keytruda Improves Head and Neck Cancer Survival by 34% in Study